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Cytokine preconditioning of engineered
cartilage provides protection against
interleukin-1 insult
Andrea R. Tan1, Curtis D. VandenBerg2, Mukundan Attur3, Steven B. Abramson3, Martin M Knight4, J. Chloe Bulinski5,
Gerard A. Ateshian1,6, James L Cook7 and Clark T. Hung1*
Abstract
Background: During osteoarthritis and following surgical procedures, the environment of the knee is rich in
proinflammatory cytokines such as IL-1. Introduction of tissue-engineered cartilage constructs to a chemically harsh
milieu may limit the functionality of the implanted tissue over long periods. A chemical preconditioning scheme
(application of low doses of IL-1) was tested as a method to prepare developing engineered tissue to withstand
exposure to a higher concentration of the cytokine, known to elicit proteolysis as well as rapid degeneration of cartilage.
Methods: Using an established juvenile bovine model system, engineered cartilage was preconditioned with low doses
of IL-1α (0.1 ng/mL, 0.5 ng/mL, and 1.0 ng/mL) for 7 days before exposure to an insult dose (10 ng/mL). The time frame
over which this protection is afforded was investigated by altering the amount of time between preconditioning and
insult as well as the time following insult. To explore a potential mechanism for this protection, one set of constructs
was preconditioned with CoCl2, a chemical inducer of hypoxia, before exposure to the IL-1α insult. Finally, we examined
the translation of this preconditioning method to extend to clinically relevant adult, passaged chondrocytes from a
preclinical canine model.
Results: Low doses of IL-1α (0.1 ng/mL and 0.5 ng/mL) protected against subsequent catabolic degradation by cytokine
insult, preserving mechanical stiffness and biochemical composition. Regardless of amount of time between
preconditioning scheme and insult, protection was afforded. In a similar manner, preconditioning with CoCl2 similarly
allowed for mediation of catabolic damage by IL-1α. The effects of preconditioning on clinically relevant adult, passaged
chondrocytes from a preclinical canine model followed the same trends with low-dose IL-1β offering variable protection
against insult.
Conclusions: Chemical preconditioning schemes have the ability to protect engineered cartilage constructs from
IL-1-induced catabolic degradation, offering potential modalities for therapeutic treatments.
Keywords: Interleukin-1, Preconditioning, Cartilage tissue engineering
Background
Articular cartilage is the connective tissue that lines the
ends of diarthrodial joints and serves to bear load and
provide lubrication during motion [1]. When the tissue
is damaged through physical injury or disease such as
osteoarthritis (OA), the healing response is limited due
to its avascular nature and limited cellularity [2]. These
types of injuries often lead to a disruption in the balance
between anabolic and catabolic regulatory activities that
lead to a phenotypic shift in chondrocytes, cell death,
and an increase in expression of inflammation-related
genes [3] that leads to a loss of cartilage matrix compo-
nents and deterioration in the structural and functional
properties of cartilage [4, 5]. Catabolic cytokines may
also be generated by the fibroblast- and macrophage-like
cells in the synovium, the thin layer that lines the non-
articulating surfaces of diarthrodial joints and maintains
a synovial fluid-filled cavity [6], in response to the
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breakdown products from damaged cartilage. Conse-
quently, elevated levels of inflammatory cytokines
such as interleukin-1 (IL-1) and tumor necrosis factor
(TNF)-α have been measured in the synovial fluid
during cartilage pathology [7, 8].
Though TNF-α is the dominant cytokine responsible
for joint swelling and acute inflammation, it has been re-
ported to be unlikely to play a role in tissue degradation
[9]. In contrast, both forms of the IL-1 isoform, IL-1α
and IL-1β, are reported to be responsible for cartilage
erosion and sustained cell infiltration, though their
concentrations are highly dependent on the stage of
osteoarthritis [9] and the model system. As such, our lab
and others have chosen to focus on the effect of IL-1 on
culture systems to better understand the mechanisms
behind erosive tissue breakdown and to potentially iden-
tify strategies for repair [10–15].
Strategies for using engineered constructs for cartilage
tissue repair have focused on the implantation of tissues
possessing the mechanical integrity and chemical forti-
tude to withstand the potentially harsh mechanochemi-
cal environment of the joint [10]. Catabolic mediators
from inflammation [16] or the surgical intervention itself
[17] have been shown to be especially pronounced in
underdeveloped tissues [10, 18] in which cells are not
fully embedded in the chondroprotective extracellular
matrix (ECM) that accompanies construct maturity.
Previous studies from our lab have reported that the lin-
gering effects of IL-1 to immature constructs remains in
long-term culture, even after the cytokine has been
removed [10]. In order to successfully utilize these con-
structs for functional repair, it is important, therefore, to
investigate potential strategies for preventing or mediat-
ing the effect of cytokines on the developing constructs.
In cardiovascular systems, cellular preconditioning
schemes by mechanical and chemical manipulation have
been used extensively to prime stem cells to a state in
which they can withstand a harsh microenvironment
[19–22]. In particular, brief exposure to a catabolic agent
afforded longer-term protection against subsequent at-
tacks, offering the most effective means of cytoprotec-
tion [23]. Previous studies have reported that hypoxia-
inducible factor 1α (HIF-1α) serves as the predominant
regulator of genes responsible for survival signaling and
is activated when cells are exposed to a preconditioning
scheme [19]. Motivated by the reported benefits of
preconditioning, we hypothesized that the catabolic
effects of injurious IL-1 on engineered cartilage could be
decreased by initially preconditioning them with low
doses of the cytokine.
This study investigates the effects of supplementing
the culture media with a low concentration of IL-1.
Specifically, the effects of a 1-week preconditioning
treatment on developing engineered cartilage constructs
is tested against exposure to a higher concentration of
the cytokine, known to elicit proteolysis as well as rapid
degeneration of cartilage [24]. This phenomenon is in-
vestigated first using a well-established juvenile bovine
chondrocyte model [25], which has been shown to pro-
duce functional material properties (Young’s modulus
(EY)) and glycosaminoglycan (GAG) content similar to
native tissue [26], providing a robust system to study
potential therapies for osteoarthritis. Then, to provide
additional support for the clinical feasibility of such a
protection method, we subsequently translated this work
to an adult canine model [27–29] to facilitate future in
vivo studies in an established large preclinical animal
model. This large animal model for articular cartilage re-
pair is commonly used and ideal as the anatomy, physi-
ology, and biomechanics of the patellofemoral joint is
similar between species [30]. Additionally, canine models
allow for multiple clinically relevant postoperative man-
agement strategies including non-weight-bearing slings,
splints, external fixators with adjustable range of motion
control, as well as underwater treadmills, leash walking,
and athletic training activities. With both of these para-
digms, the use of a physiologically relevant tissue to
study this method of protection against cytokine expos-
ure may shed light on the behavior of in situ cartilage
during injury or disease.
Methods
Experimental design
Four consecutive studies are described here and laid out
in Fig. 1. For the first three studies, we used a bovine
model of chondrocytes from skeletally immature animals,
as they are readily available, well characterized, and cap-
able of growing robust tissue in culture (relative to adult
cells). Additionally, use of juvenile bovine chondrocytes
facilitates comparisons to our previous work, including
the response of these cells to in vitro applications of IL-1α
(10 ng/mL, [10]). In study 1, we investigated the protec-
tion afforded by low-dose preconditioning to understand
how this chemical regime could be implemented for
therapeutic applications. Briefly, constructs were allowed
to elaborate a threshold amount of ECM (attaining a EY of
at least 100 kPa), exposed to a low-dose concentration of
IL-1α for 7 days and then subjected to an injurious level
of cytokine for the final 7 days. In study 2, we looked
further at the time-dependent profile of preconditioning
on the protection afforded by varying the specific timing
of the preconditioning scheme and the insult to answer
two questions: (1) how long does protection last? and (2)
how effective is the preconditioning scheme after an
interim period? Then, in study 3, we investigated the
potential role of the survival signal hypoxia-inducible factor
(HIF)-1α in affording this protection, similar to the mech-
anism suggested for hypoxic and ischemic preconditioning
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schemes [31, 32]. For this purpose, juvenile bovine con-
structs were preconditioned with cobalt chloride (CoCl2), a
chemical inducer of HIF-1α, and then exposed to an insult
dose of IL-1α to investigate whether HIF-1α upregulation
was sufficient to provide protection against catabolic
effects. Finally, in study 4, we investigated whether the
noted trends carry over to a preclinical canine model using
chondrocytes from skeletally mature animals.
Tissue isolation and cell culture
All bovine studies were Columbia Institutional Animal
Care and Use Committee (IACUC)-exempt. Canine
studies were performed under University of Missouri
IACUC approval (ACUC number 7332). Articular cartil-
age was harvested from knee joints of either freshly
slaughtered 2–4-week-old bovine calves or from adult
dogs. Four to six joints were used for each experiment
and cells were pooled from all joints. In study 4, cartilage
was digested in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) with collagenase IV (Worthington
Biochemical Corporation, Lakewood, NJ, USA) for 11 h at
37 °C with shaking. Cell suspensions were filtered through
a 70-μm porous mesh and sedimented in a bench-top
centrifuge for 15 min at 1500 g. Viable cells were counted
with a hemocytometer and trypan blue and plated at high
density (20 × 103 cells/cm2) in a growth factor cocktail
(1 ng/mL transforming growth factor (TGF)-β1, 5 ng/mL
basic fibroblast growth factor (bFGF), and 10 ng/mL
platelet-derived growth factor (PDGF)-ββ [27, 33]). At
confluence, cells were trypsinized, resuspended (60 × 106
cells/mL), and mixed in equal parts with 4 % low-gelling
agarose (type VII, Sigma-Aldrich, St. Louis, MO, USA) at
37 °C. The chondrocyte/agarose mixture was cast into
slabs and cores were produced using a sterile, disposable
biopsy punch (Integra Miltex, York, PA, USA) to yield
final dimensions (4 mm× 2.34 mm thick). Constructs
were cultured in DMEM supplemented with 1× penicillin,
streptomycin, fungizone (PSF, Sigma-Aldrich), 0.1 μM
dexamethasone, 40 μg/mL L-proline, 100 μg/mL sodium
pyruvate, and 1× ITS+ premix (insulin, human transferrin,
and selenous acid, Becton Dickinson, Franklin Lakes, NJ,
USA). Medium was further supplemented with 50 μg/mL
ascorbate 2-phosphate daily and 10 ng/mL TGF-β3
(Invitrogen, Carlsbad, CA, USA) for the first 14 days of
culture and was changed every other day.
Preconditioning and insult
Earlier studies have identified that constructs must com-
prise sufficient extracellular matrix (ECM) to withstand
the harsh catabolic effects of IL-1 [10]. Accordingly, for
the current studies, constructs were allowed to attain an
equilibrium Young’s modulus (EY) of at least approxi-
mately 100 kPa (for bovine) and approximately 150 kPa
(for canine) before the application of any cytokine. For
study 1, IL-1α, the more potent of the two isoforms in
juvenile bovine agarose-chondrocyte constructs [11],
was administered (0.1 ng/mL, 0.5 ng/mL, 1.0 ng/mL) for
7 days before an insult dose (10 ng/mL) was added to
the culture medium for the final 7 days. In study 2, a
subset of the preconditioning doses from study 1 was ad-
ministered for 7 days based on the success at mitigating
the effects of interleukin exposure (0.1 ng/mL, 0.5 ng/mL)
Fig. 1 Schematic of experimental design. Studies 1 through 3 utilized the well-established juvenile bovine model system. Study 1 examined the
protection afforded by low-dose IL-1α exposure. Study 2 investigated the time-dependent effects of preconditioning on protection by applying
an immediate and delayed insult. Study 3 examined the effect of CoCl2 preconditioning to investigate a potential mechanism of protection. Study
4 explored the translational potential of preconditioning schemes by characterizing the effect on clinically relevant adult passaged canine chondrocytes.
CoCl2 cobalt chloride, IL-1 interleukin-1
Tan et al. Arthritis Research & Therapy  (2015) 17:361 Page 3 of 12
when constructs reached sufficient ECM deposition. The
7-day insult dose was then applied either immediately
following the preconditioning (immediate insult, Fig. 1,
orange block) or after 7 days had elapsed (delayed insult,
Fig. 1, pink block). In study 3, in place of preconditioning
with interleukin dosing, constructs were exposed to media
supplemented with 100 μM CoCl2 before the insult dose
was administered. To parallel the conditions of study 1, in
study 4, IL-1β (0.2 ng/mL, 1.0 ng/mL, 2.0 ng/mL), the
more potent isoform for canine constructs, was used [28,
29] for 7 days before an insult dose (10 ng/mL) was added
to the culture medium for the final 7 days. For all studies,
a negative control group was included where samples
were handled similarly but no preconditioning or insult
dosage was applied. A positive control group (labeled
0 ng/mL) was also included where preconditioning was
not applied, but samples were exposed to the insult dose
of IL-1. During the period of cytokine (both precondition-
ing and insult) and CoCl2 exposure, all media was void of
dexamethasone, previously shown to counter the catabolic
effects of IL-1 [10].
Mechanical testing
Constructs were tested for their equilibrium EY and
dynamic modulus (G*) in unconfined compression using
a custom computer-controlled system [34]. An initial
0.02 N tare load was applied, followed by compression
to 10 % strain, at a strain rate of 0.05 % s−1. After stress
relaxation was achieved, a 2 % peak-to-peak strain was
superimposed at 0.01Hz. EY was measured from the
stress–relaxation equilibrium response and is used as a
measure of the equilibrium behavior of cartilage after an
applied load has been applied. G*, considered to be a
more physiologically relevant measurement of cartilage
behavior in response to applied cyclic loads, was deter-
mined from the slope of the stress–strain response
under dynamic loading.
Biochemical analysis
After material testing, half of the construct was dried
and digested in proteinase K solution overnight at 56 °C,
as described previously [35], and the other half was
preserved for histology (see below). Specifically, the
biochemical content of each sample was assessed by
measuring the sample wet weight, lyophilizing, and then
measuring the dry weight. Construct swelling was
quantified by measuring the gross water content of the
constructs [26]. Following digestion, one aliquot was an-
alyzed for GAG content via the 1,9 dimethylmethylene
blue dye-binding assay. A second aliquot was hydrolyzed
with 12 N HCl at 110 °C for 16 h, dried, and resuspended
in assay buffer. Orthohydroxyproline (OHP) content was
determined using a colorimetric assay via a reaction with
chloramine T and dimethylaminobenzaldehyde, scaled for
microplates [35]. Overall collagen content was calcu-
lated using a 1:7.64 OHP-to-collagen mass ratio [36].
Total double-stranded DNA content was assessed by
the Picogreen assay, following the manufacturer’s
standard protocols.
Histological analysis
The other half of each sample was fixed in acid-formalin,
paraffin-embedded, sectioned (8 μm thick), and stained
for histology to assess cellular (hematoxylin and eosin),
proteoglycan (Safranin O), and collagen (Picrosirius Red)
distribution and organization. Immunohistochemistry was
also performed to confirm the development of collagen II
in constructs. Briefly, tissue sections were digested in
5.0 mg/mL testicular hyaluronidase (Sigma-Aldrich),
swollen in 0.5 mol/L acetic acid, and blocked in 10 %
normal goat serum (NGS). Sections were labeled with
types I and II collagen (Abcam, Cambridge, MA,
USA) and visualized with Alexa Fluor 488-conjugated
secondary antibody labeling (Molecular Probes, Eugene,
OR, USA) and diamidino-2-phenylindole nuclear counter-
staining (Molecular Probes). Sections were observed on a
laser scan confocal microscope and a tile scan was
performed to visualize the entire tissue slice (Carl Zeiss
Microscopy, LLC, Thornwood, NY, USA).
Statistics
Statistical analyses were performed using two-way
analysis of variance (ANOVA) with Tukey’s honest
significant difference post hoc tests (Statistica; StatSoft
Inc., Tulsa, OK, USA), with α = 0.05 and statistical
significance set at p ≤ 0.05 to compare groups across day
and treatment. Data is reported as the mean and
standard deviation of four to five samples per time
point and group.
Results
Study 1: low-dose preconditioning affords protection
against subsequent IL-1 exposure
All four studies were started on constructs that had ma-
tured, i.e., elaborated sufficient ECM to resemble in situ
cartilage. For these constructs, maturation in culture to
day 21 yielded significantly greater mechanical stiffness
and biochemical content compared with initial day 0 con-
ditions (EY = 96.8 ± 22.3 kPa, GAG = 1.16 ± 0.26 %/ww).
Constructs were then exposed to low doses of IL-1α. At
day 28, control constructs continued to elaborate matrix
and increase stiffness, while those constructs exposed to
low doses of IL-1α showed significantly lower mech-
anical stiffness and GAG composition, demonstrating
a concentration-dependent degrading action of the cyto-
kine. For example, with 0.1 ng/mL and 0.5 ng/mL doses,
slight tissue degradation was noticeable, as evidenced by
the 25 % drop in mechanical properties compared to
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control samples (p < 0.05, Fig. 2a). A corresponding 15 %
and 22 % drop in GAG content, respectively, was noted
for those same low-dose concentrations, however the
0.5 ng/mL preconditioning dose elicited a significantly
lower GAG content relative to control samples (p = 0.03,
Fig. 2a). When 1.0 ng/mL IL-1α was introduced into the
culture medium, however, the catabolic effects were much
more severe, significantly lowering mechanical stiffness by
nearly 55 % (p = 0.0001). Interestingly, the decrease in
GAG content did not mirror the significant drop in mech-
anical properties; instead, a more moderate 27 % decrease
was measured compared to control samples (p = 0.004).
Collagen content was unchanged across all groups.
Following 7 days of insult culture (10 ng/mL IL-1α), a
differential response was noted between positive control
and preconditioned constructs. To evaluate the effect of
preconditioning, construct properties were normalized
to negative control values. Notably, positive control
samples showed a significant degree of degradation,
retaining only 23 % of the construct’s mechanical
stiffness (p < 0.0001) and 40 % of the construct’s GAG
content (p < 0.0001, Fig. 2b). In comparison, precondi-
tioning constructs with low doses of IL-1α the week
prior to the insult culture afforded dose-dependent pro-
tection against catabolic degradation. With 0.1 ng/mL
IL-1α preconditioning, slight protection was afforded.
That is, though significantly lower in mechanical
stiffness (p = 0.001) and GAG content (p = 0.007) than
negative control samples, these constructs exhibited
significantly greater mechanical stiffness (p = 0.04) and
GAG content (p = 0.04) than positive control samples. In
contrast, 0.5 ng/mL IL-1α preconditioning provided even
greater protection against degradation, with mechanical
stiffness and GAG content higher than positive control
samples (p < 0.05), and more importantly, similar to nega-
tive control constructs (p > 0.05, Fig. 2b). There is a limit
to the observed protection afforded by preconditioning;
when constructs were exposed to the highest precondi-
tioning dose of IL-1α (1.0 ng/mL), they showed a similar
degradation profile as that seen with positive control
samples, exhibiting comparable decreased mechanical
stiffness (p = 0.99) or GAG content (p > 0.99). Collagen
content was maintained across all groups, regardless of
IL-1 exposure. Similarly, DNA content and construct
swelling was not significantly altered across any group for
all time points (data not shown, p > 0.05).
Study 2: protection against IL-1 effects is sustained after
delayed insult
Preconditioning schemes were capable of maintaining
the mechanical integrity and biochemical makeup of
constructs even over extended timescales. During the
preconditioning phase (Fig. a, b green shaded region),
low levels of IL-1α (0.1 ng/mL and 0.5 ng/mL) exposure
did not significantly alter the mechanical or biochemical
composition of the constructs relative to control samples
(p > 0.05). Similarly, DNA content and construct swelling
was not significantly altered across any group (data not
shown, p > 0.05).
The protection afforded by preconditioning following
immediate insult (Fig. 3a, dark orange shaded region)
mimicked the findings from study 1: a significant drop
in properties was observed for positive control samples
(p < 0.0001). These catabolic changes were mitigated
with 0.1 ng/mL preconditioning exposure (p = 0.01) and
protected against with 0.5 ng/mL preconditioning
Fig. 2 Study 1. (a) Young’s modulus (EY) and GAG content at day 28 as a result of preconditioning juvenile bovine constructs with low doses of
IL-la. (b) Normalized EY and GAG content at day 35 after 7 days of exposure to an insult dose of IL-lα (10 ng/mL). *p < 0.05 vs. control, #p < 0.05 vs.
positive control (0 ng/mL). GAG glycosaminoglycan, IL-1 interleukin-1
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exposure (p = 0.93). When insult was removed for the
following 7 days, similar trends were noted and the
mechanical properties and biochemical content were
sustained (Fig. 3a, light orange shaded region).
When samples were cultured for a 7-day interim
period following preconditioning, mechanical properties
and biomechemical content were unchanged (Fig. 3b,
light green shaded region). Delayed insult (Fig. 3b, pink
shaded region) produced similar effects on positive
control samples as after immediate insult (% degradatio-
nimmediate = 0.67 ± 0.09 vs. %degradationdelayed = 0.56 ±
0.09, p = 0.13). Preconditioning with 0.1 ng/mL IL-1α,
however, did not show the same protective benefits seen
previously; instead, constructs exhibited a significant
decrease in Young’s modulus (p < 0.0001), similar to
positive control constructs (p = 0.62). Biochemical con-
tent was unchanged from control samples (p > 0.05). In
contrast, constructs preconditioned with 0.5 ng/mL IL-
1α continued to exhibit partial protection from catabolic
degradation, retaining 76 % of their mechanical stiffness
and comparable GAG content (p = 0.98) compared to
control samples. This protection reflects a significant
improvement in mechanical functionality compared to
positive control samples (p = 0.005).
For both immediate and delayed insult schemes,
0.5 ng/mL IL-1α offered a degree of protection against
the supraphysiologic IL-1α exposure; histological stains
confirmed these findings. Control constructs exhibited
uniform cellularity (Fig. 4a) throughout the construct
that produced robust GAG staining (Fig. 4e) accompan-
ied by pockets of intense collagen formation throughout
the construct (Fig. 4i). Immunohistochemistry confirmed
the presence of collagen II, with patterns of greater in-
tensity mimicking the pockets identified with Picrosirius
Red stain (Fig. 4m). Positive control samples revealed a
large distinct border of GAG depletion (Fig. 4f, denoted
by arrows), though overall bulk collagen distribution was
unchanged from control samples (Fig. 4j vs. 4i). Specific
collagen II staining of positive control samples however,
revealed an intense counter border to the depleted GAG
molecules (Fig. 4n). Constructs exposed to 10 ng/mL IL-
1α immediately following preconditioning revealed a
similar appearance as control constructs (Fig. 4g, k, o).
In contrast, when constructs were exposed to delayed
10 ng/mL IL-1α insult, although overall GAG content
was statistically similar, distribution was partially hetero-
geneous across the entirety of the construct with a slight
depletion of GAG at the border of the construct (Fig. 4h,
yellow arrow).
Study 3: CoCl2 preconditioning offers similar protection
scheme
In study 3, in lieu of preconditioning with low doses of
cytokine, we explored the use of CoCl2 as a means of
activating HIF-1α transcription. On day 14, prior to the
start of CoCl2 preconditioning, constructs possessed
appreciable ECM deposition and associated mechanical
properties similar to those in mature constructs used in
studies 1 and 2 (EY = 174 ± 13.8 kPa; GAG = 3.21 ±
0.20 %/ww). Following preconditioning with CoCl2, con-
structs exhibited significantly lower stiffness (p = 0.0076,
Fig. 5a), but comparable dynamic modulus, GAG, and
Fig. 3 Study 2. Young’s modulus (EY) and GAG (%/ww) for juvenile bovine constructs over time for (a) immediate and (b) delayed insult. Color
blocks indicate treatment group (Fig. 1). *p < 0.05 vs. control, #p < 0.05 vs. positive control (0 ng/mL). GAG glycosaminoglycan
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collagen content compared to control constructs (p > 0.05).
Following insult with 10 ng/mL IL-1α, positive control
samples behaved similarly to those in studies 1 and 2, sig-
nificantly degrading in mechanical properties (p < 0.0001)
and GAG content (p < 0.0001) compared to control sam-
ples. Collagen content for these positive control samples
was statistically similar to control samples. CoCl2-precon-
ditioned constructs showed resistance to the catabolic
degradation imparted by IL-1α and were capable of retain-
ing more of their GAG content (p = 0.04, Fig. 5b), leading
to improved mechanical properties (p = 0.02) com-
pared to positive control samples. Contrary to previ-
ous findings that collagen content is unchanged
following in vitro IL-1α application, here, we note a
decrease in collagen content for CoCl2-preconditioned
constructs (p < 0.0001), though DNA content and
construct swelling was not significantly altered across
any group (data not shown, p > 0.05).
Study 4: exploring clinical translation feasibility with adult
canine chondrocytes
Similar to bovine chondrocytes, adult canine chondro-
cytes first elaborated significant amount of ECM
resulting in increased mechanical properties and bio-
chemical composition by day 14 (EY = 191 ± 17.0 kPa,
GAG = 3.33 ± 0.16 %/ww). By day 21, after 7 days of
low-dose concentrations of IL-1β, all constructs
showed continued mechanical functionality that was
not significantly altered by the addition of the cyto-
kine (p > 0.05, Fig. 6a). However, unlike for bovine
chondrocytes, constructs comprised of canine chon-
drocytes revealed a change in DNA content following
IL-1β application. To account for this change, GAG
content was reported as a function of DNA content,
reflecting the biosynthetic output of the cells. Accord-
ingly, the GAG production after low-dose IL-1β pre-
conditioning was similar to control samples (p > 0.05,
Fig. 4 Study 2. Histological stains for cellularity (H&E), GAG (Safranin 0), bulk collagen (Picrosirius Red), and collagen II (Alexa Fluor 488) distribution for
juvenile bovine constructs exposed to IL-1α insult in the (b, f, j, n) absence of or after (c, g, k, o) immediate and (d, h, i, p) delayed insult schemes
(0.5 ng/mL). Scale bar = 0.5 mm. Arrows indicate depleted ECM matrix. ECM extracellular matrix, GAG glycosaminoglycan, H&E hematoxylin and eosin,
IL-1 interleukin-1
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Fig. 6a). Collagen content and construct swelling were
also unchanged.
Following cytokine insult (10 ng/mL IL-1β), positive
control samples exhibited significant decreases in
mechanical stiffness (p < 0.0001, Fig. 6b) and GAG
content (p < 0.0001, Fig. 6b). Low-dose concentrations of
0.2 ng/mL IL-1β offered mediation of catabolic degrad-
ation reflected in mechanical properties by retaining a sig-
nificantly higher Young’s modulus compared to positive
control samples (p = 0.01, Fig. 6b). The partial protection
noted for mechanical properties was not reflected in the
biochemical composition of the samples, however; GAG/
DNA produced by cells exposed to 0.2 ng/mL IL-1β was
statistically similar to positive control samples (p = 0.74).
The reverse trend was seen for higher (1.0 and 2.0 ng/mL)
preconditioning doses of IL-1β; mechanical properties
were similarly affected by the insult level of cytokine as
positive controls (p > 0.05, Fig. 6b) though GAG content
Fig. 5 Study 3. (a) Young’s modulus (EY) and GAG content at day 21 after 7 days of reconditioning juvenile bovine chondrocytes with 100 μM CoCl2.
(b) Normalized EY and GAG content at day 28 after insult dose of 10 ng/mL IL-lα was administered. *p < 0.05 vs. control, #p < 0.05 vs. positive control
(0 μM CoCI2). GAG glycosaminoglycan, IL-1 interleukin-1
Fig. 6 Study 4. (a) Young’s modulus (EY) and GAG content at day 21 as a result of preconditioning adult canine chondrocytes with low doses of
lL-1β. (b) Normalized EY and GAG content at day 28 after 7 days of exposure to an insult dose of IL-lα (10 ng/mL). *p < 0.05 vs. control, #p < 0.05
vs. positive control (0 ng/mL). GAG glycosaminoglycan, IL-1 interleukin-1
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recovered and was comparable to negative control sam-
ples (p < 0.05). Collagen content and construct swelling
were unaffected for all groups.
Discussion
Cartilage grafts introduced to an injured or arthritic
joint are likely to be subjected to a cytokine-rich envir-
onment. Thus, in order to promote engineered cartilage
as a clinically relevant replacement tissue, the construct
must be able to survive the chemical and mechanical
loads that are imparted upon implantation. In this con-
text, we explored a protection method by which func-
tional engineered cartilage constructs that are capable of
attaining native functional properties (approximately
400–1000 kPa [26, 37]; canine: approximately 190–380
kPa [27, 38]) can better withstand the harsh chemical
environment of the joint. To our knowledge, this is the
first study to show that chemical preconditioning
schemes impart protection against injurious IL-1 expos-
ure. Specifically, by varying the preconditioning dose, we
were able to identify conditions under which mechanical
properties and biochemical composition were signifi-
cantly retained, despite subsequent exposure to injurious
levels of the cytokine, even when the insult is delayed.
These results support our hypothesis regarding the
benefits of cytokine preconditioning and suggest that
preconditioning in a clinical therapeutic context may be
feasible as time between preconditioning and insult does
not completely remove the protective benefits observed.
Furthermore, we have noted successful translation of
these results from a bovine model into a large pre-
clinical animal model system. Future work exploring
the mechanisms behind this protection and the differ-
ential mediators is necessary; nevertheless, this early
data serve as encouragement for the eventual applica-
tion of preconditioning techniques to therapies for
cartilage repair in the clinic.
The use of clinically available human cells in functional
tissue engineering may introduce additional factors that
may influence the utility of preconditioning as we have
described here. For example, while differentiated adult
chondrocytes may be obtained from a patient’s own
healthy, non-load-bearing cartilage, this may lead to donor
site morbidity and further tissue degeneration [39]. As an
alternative, chondrocytes from the diseased knee may also
be harvested during preliminary debridement procedures.
It is unknown, however, how such cells isolated from
diseased (e.g., arthritic) tissue will function. Further assess-
ment is needed to understand whether the cells maintain
an osteoarthritic phenotype and whether the cell memory
of the in vivo environment will influence the precondi-
tioning scheme. To circumvent these potential problems,
it may be more advantageous to use chondrocytes derived
from juvenile articular cartilage, as they have already been
shown to rapidly grow and produce significantly greater
levels of cartilage macromolecules than cells derived from
adult cartilage [40].
While many studies employ a classical concept of pre-
conditioning involving cyclical exposure to brief episodes
[20, 41, 42], other studies utilized a single long-term
exposure [21, 31, 43, 44] to initiate survival signaling
that was then followed by the harmful insult. We chose
to adopt the latter as the longer preconditioning time
frame would increase the likelihood of the cytokine
diffusing fully through the agarose construct within the
preconditioning period. It is important to note, however,
that while the protective effect we observed here has
been previously noted with other chemical schemes to
prepare individual cells against harsh conditions [19, 23],
this is the first time the effect has been observed for
complex whole tissues that include elaborated extracel-
lular matrix. The dense matrix in cartilage constructs
confounds attempts to understand the potential mecha-
nism(s) of protection. That is, the mode of protection
may arise from an altered state of the cells themselves,
or because the preconditioning has induced the cells to
develop a chondroprotective matrix that is able to medi-
ate the effects of the cytokines.
Previous studies have supported the idea that a
cell’s tolerance to subsequent insult events is afforded
by activation of a survival signal that depends on
multiple signaling pathways or on the release of
chemical activators such as adenosine or nitric oxide [41].
Furthermore, other studies have found that modulation of
growth factor expression either through the use of specific
factors during expansion [23] or through genetic manipu-
lation can produce similar beneficial preconditioning ef-
fects. Further studies are necessary to systematically
identify which pathways are involved in the protective
process; however, we can postulate that, in agreement with
previous preconditioning studies [31, 32] and as
supported by the results we observed, the HIF-1α
pathway has a central role in the activation of this
survival signal against IL-1 catabolic degradation. In-
deed, other groups have found the transcription factor
regulates not only proinflammatory mediators, but
also glucose transport, anaerobic energy generation,
and matrix synthesis. [45, 46]. These downstream ef-
fects may concomitantly work to preserve cartilage
integrity during insult.
Despite the protection afforded by preconditioning,
however, we noted a decrease in collagen content
after preconditioning with CoCl2 (data not shown) that
was not seen with IL-1 preconditioning groups. This may
point to the possibility that a downstream effect of indu-
cing hypoxia may be an upregulation of collagenases that
did not occur in our other preconditioning scheme.
Additionally, though we did not directly assay for HIF-1α
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upregulation, previous studies have found an association
between hypoxia induction with the upstream activation
of the p38 mitogen-activated protein (MAP) kinase path-
way [47]. p38 MAP kinase has been found to upregulate
cytokine production via direct phosphorylation of
transcription factors [48], possibly leading to additional
catabolic effects on the bulk construct. Further work will
be necessary to fully elucidate this possibility. Neverthe-
less, preconditioning with a low dose of IL-1 had a similar
effect as preconditioning with induced hypoxia, suggesting
that the downstream effect of IL-1 preconditioning may
be attributable to upregulation of HIF-1α or a similar
effect on cellular transcription.
The heightened generation of a chondroprotective
matrix is unlikely to be the only cause of the protection.
Previous studies have suggested that pools of GAG in
the pericellular region and interterritorial regions change
with culture time such that changes to the local environ-
ment of the cell alter the cell’s function and response to
external stimuli such as IL-1 [49–52]. This local matrix
forms around day 4 in culture, making the cells stiff
inclusions in a soft matrix (agarose gel), but with time in
culture, this cell-associated matrix modulates the sensi-
tivity to chemical factors. However, under our current
experimental conditions, unlike previously reported stud-
ies [10], we have observed vulnerability to IL-1 regardless
of mechanical integrity or biochemical composition, thus
ruling out extensive cytoprotection by matrix compo-
nents. Furthermore, samples with the same composition
and mechanical integrity responded differently to insult
levels of IL-1 depending on their preconditioning (none
vs. low-dose IL-1 vs. CoCl2 treatment). It is important to
note, however, that our measurements of bulk proper-
ties and biochemical constituent content may not de-
tect compositional changes to the matrix. Changes in
the composition of matrix could be responsible for
the protection against IL-1 that preconditioning with
either low-dose IL-1 or CoCl2 elicits. Further analysis,
however, using comprehensive proteomics gene ex-
pression arrays will be required to better understand
whether changes to the matrix or subsequent cellular
changes are responsible for resisting the catabolic
damage brought about by IL-1 exposure.
Finally, although the concentration of the cytokine used
to impart damage to the tissue was on par with concentra-
tions typically utilized for in vitro studies (5–20 ng/mL
[14, 53, 54]), the dose we used is well above doses found
in vivo (0.01–0.2 ng/mL [12, 55]). Nevertheless, given the
level of protection seen here in the presence of supraphy-
siologic IL-1 insults level, we anticipate that in the pres-
ence of lower, more clinically relevant levels, protection
would similarly be afforded. As described in these studies,
we reason that in free swelling conditions, in the absence
of any mechanical loading, a higher concentration of
cytokine would be necessary to elicit an injurious effect
relatively quickly. In fact, previous studies have demon-
strated that engineered cartilage is insensitive to interleu-
kin at ≤ 0.01 ng/mL, and exhibits an all-or-nothing
response at IL concentrations from 0.1 to 10 ng/mL [11].
Theoretical modeling of dynamic deformational loading of
hydrogels such as agarose have predicted that loading
leads to enhanced transport of soluble factors such as
growth factors and cytokines [56–59]. Accordingly, it may
be possible to utilize more physiologic levels of cyto-
kines in tandem with dynamic loading protocols in
future evaluations of preconditioning schemes for
tissue-engineered cartilage [26] to gain further in-
sights into clinical feasibility.
Conclusions
Here, we have described a novel method for desensitizing
engineered cartilage to cytokine exposure, effectively
protecting constructs from complete catabolic degrad-
ation. Though preconditioning protocols have been
investigated and are widely recognized for their use in
hypoxic and ischemic conditions, this is the first time
such a protocol has been applied for protection
against cytokine insult. Preconditioning with a low
dose of IL-1α immediately is capable of protecting
the construct against subsequent catabolic destruction
from exposure to injurious levels of cytokine and pro-
vides an intriguing potential for using this technique
for clinical therapeutic applicability.
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